CTOs on the Move

Mind Medicine

www.mindmed.co

 
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mindmed.co
  • One World Trade Center Suite 8500
    New York, NY USA 10007
  • Phone: 203.648.5275

Executives

Name Title Contact Details
Bradford Cross
Chief Technology Officer Profile
Bradford Cross
Chief Technology Officer Profile

Funding

Mind Medicine raised $24M on 02/27/2020
Mind Medicine raised $25M on 10/09/2020

Similar Companies

Fraunhofer Center for Laser Technology

Fraunhofer Center for Laser Technology is a Plymouth, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcxis Biotechnologies Inc

Arcxis Biotechnologies Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Qvin

Take control of your health in the most natural way possible.

iCyt Mission Technology

iCyt Mission Technology is a Champaign, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fate Therapeutics

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company`s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Company`s immuno-regulatory product candidates include ProTmune™, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA.